Unlocking gene control mechanisms to develop small molecule therapies


Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.


Year Invested: 2016
Location: Cambridge, MA
Visit: www.fulcrumtx.com

Recent News

February 7, 2017
Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

December 7, 2016
Fulcrum Therapeutics Appoints Renowned Experts in CNS Disorders and Muscular Dystrophies to Serve on Newly Formed Scientific Advisory Board

September 19, 2016
FierceBiotech names Fulcrum Therapeutics as one of its “Fierce 15” Biotech Companies of 2016

Read More News

Associated Team Members

Mark Levin
Partner

Philip Reilly, M.D., J.D.
Venture Partner